Kongresser

Nyheter
Sykdommer
Kongresser
Samfunnet
ASCO
EHA

ASCO Antall artikler: 11

EHA Antall artikler: 8

Registrer deg for nyhetsbrev

For at du skal få adgang til vårt gratis nyhetsbrev, trenger vi informasjon om din yrkestittel og arbeidsplass - så vi kan verifisere at du får tilgang til de annonsene som nyhetsbrevet inneholder.

Abonner på nyhetsbrev

For at du skal få adgang til vårt gratis nyhetsbrev, trenger vi informasjon om din yrkestittel og arbeidsplass - så vi kan verifisere at du får tilgang til de annonsene som nyhetsbrevet inneholder.

Navn *

Please enter your name!

Email *

Please enter your email!

Yrkestittel *

Arbeidsplass *

Arbeidsplass

Sikkerhet *

Send me a copy

Nyheter fra ESMO

FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours Evidence for efficacy is based on the results from the LIBRETTO-001 study

Created on: Sep 30, 2022 | 08:36 am

Sep 30, 2022 | 08:36 am
Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam, Netherlands Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam, Netherlands The Molecular Analysis for Precision Oncology Congress 2022 (MAP) is the yearly appointment where leading experts discuss current and future challenges in the rapidly developing field of precision oncology, with the aim of identifying targetable alterations through molecular profiling, to provide the[…]

Created on: Sep 29, 2022 | 12:00 pm

Sep 29, 2022 | 12:00 pm
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC FDA also approved the Oncomine Dx Target Test as a companion diagnostic for selpercatinib

Created on: Sep 29, 2022 | 09:00 am

Sep 29, 2022 | 09:00 am
Utility of Genomic Profiling of cfDNA to Inform Clinical Care for Patients with Advanced Biliary Tract Cancer Utility of Genomic Profiling of cfDNA to Inform Clinical Care for Patients with Advanced Biliary Tract Cancer Limitations of cfDNA for detection of FGFR2 fusions

Created on: Sep 28, 2022 | 15:33 pm

Sep 28, 2022 | 15:33 pm
Higher Efficacy, But Also More Toxicity of Axicabtagene Ciloleucel Compared to Tisagenlecleucel in Relapsed/Refractory DLBCL Higher Efficacy, But Also More Toxicity of Axicabtagene Ciloleucel Compared to Tisagenlecleucel in Relapsed/Refractory DLBCL Findings from an individual patient data based matched comparison of efficacy and safety between two commercial CAR T cell products

Created on: Sep 27, 2022 | 12:07 pm

Sep 27, 2022 | 12:07 pm

Powered by Warp Theme Framework

Nyheter
Sykdommer
Kongresser
Samfunnet
ASCO
EHA